Welcome to our dedicated page for REPLIGEN SEC filings (Ticker: RGEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on REPLIGEN's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into REPLIGEN's regulatory disclosures and financial reporting.
FMR LLC and Abigail P. Johnson report a 5.1% beneficial stake in Repligen Corp common stock. As of December 31, 2025, they report beneficial ownership of 2,891,140.17 shares, representing 5.1% of the outstanding common stock. FMR LLC has sole voting power over 2,876,401.55 shares and sole dispositive power over 2,891,140.17 shares, while Abigail P. Johnson has sole dispositive power over the same 2,891,140.17 shares with no voting power. The securities are certified as being held in the ordinary course of business and not for the purpose of changing or influencing control of Repligen. One or more other persons may have rights to dividends or sale proceeds, but no single such interest exceeds five percent of the class.
Repligen Corporation reported new equity awards to its Chief Product Officer, Douglass Brian Robb. On 12/31/2025, he received 2,288 restricted stock units, each representing one share of Repligen common stock. These restricted stock units vest in substantially equal annual installments over three years, beginning on the first anniversary of the grant date, and are settled only in shares of common stock.
On the same date, he was also granted a stock option for 2,143 shares of common stock at an exercise price of $163.86 per share, expiring on 12/31/2035. Following the restricted stock award, he directly beneficially owned 8,540 shares of common stock, and 2,143 stock options were beneficially owned directly after the option grant.
Repligen Corporation’s Chief Product Officer, Douglass Brian Robb, reported his beneficial ownership as of December 31, 2025. He directly holds 6,252 shares of Repligen common stock, which include restricted stock units granted on May 7, 2024 (4,000 units vesting in equal annual installments over five years) and on March 1, 2025 (2,252 units vesting in equal annual installments over four years).
He also holds two stock option awards, each exercisable for Repligen common stock at an exercise price of $167.72 per share and expiring on May 7, 2034: one covering 2,980 shares, with 596 shares already vested and the remainder vesting annually from May 7, 2026 through May 7, 2029, and another covering 7,020 shares, with 1,404 shares vested and the rest vesting on the same schedule. All reported holdings are listed as directly owned.
A director of Repligen Corp (RGEN) reported a small open-market sale of company stock. On 12/17/2025, the director sold 275 shares of Repligen common stock at a price of $161 per share, as shown in Table I of the filing. After this transaction, the director continued to beneficially own 91,821 shares of Repligen common stock, held as a direct ownership position. The report was filed as a Form 4 for one reporting person, indicating routine insider transaction disclosure.
Repligen Corporation reported that one of its directors exercised a stock option for common shares. On 12/16/2025, the director acquired 3,366 shares of common stock through an option exercise at a price of $26.12 per share, increasing the director’s direct beneficial ownership to 36,622 common shares after the transaction. The related stock option, which is fully vested and exercisable, covers 3,366 shares of common stock and carries an exercise price of $26.12 with an expiration date of May 11, 2026.
A director of Repligen Corporation reported an insider transfer of 2,000 shares of Repligen common stock on 12/04/2025. After this transaction, the reporting person beneficially owns 98,959 shares of common stock in direct form. The filing describes the move as a transfer of shares in which the reporting person is a joint tenant with right of survivorship, indicating a change in how the shares are held rather than a typical market sale.
Repligen Corporation (RGEN) reported an insider stock sale by its Chief Executive Officer, who is also a director. On 11/25/2025, the executive sold 7,041 shares of common stock at a price of $170 per share, as shown in a Form 4 filing. After this transaction, the executive directly held 35,898 shares of Repligen common stock.
The sale was carried out under a pre-arranged Rule 10b5-1 trading plan that was adopted on December 12, 2024, which is designed to allow insiders to sell shares according to a set schedule.
Repligen Corporation's Chief Operating Officer reported a stock sale in a Form 4. On 11/18/2025, the officer sold 2,191 shares of Repligen common stock in an open market transaction coded "S" (sale). The weighted average sale price was $151.21 per share, with individual trades executed between $151.21 and $151.62.
After this transaction, the officer directly beneficially owns 21,520 shares of Repligen common stock. The filing notes that detailed trade breakdowns by price within the range are available upon request from the company, its security holders, or the SEC staff.
Repligen Corporation director reported several transactions in company stock. On 11/13/2025, the director sold multiple blocks of common stock in open-market transactions at weighted average prices ranging from $151.01 to $157.11, each sale covering different share amounts. After these sales, the director beneficially owned 80,743 shares of Repligen common stock in direct form. The director also exercised a stock option for 2,952 shares at an exercise price of $33.87, which increased directly held shares while reducing the option position.
Repligen (RGEN) reported an insider transaction by a director on 11/12/2025. The director exercised 25,000 stock options at $33.87 and, on the same day, sold 25,000 common shares in multiple trades under a Rule 10b5-1 plan adopted on December 9, 2024. Sale prices were reported as weighted averages ranging from $154.92 to $158.51.
Following these transactions, the director directly owned 100,743 shares. The option reported expires on 03/01/2028, with 157,344 derivative securities beneficially owned after the transactions, and remaining tranches vesting 28,777 on 03/01/2026 and 28,778 on 03/01/2027.